QUO VADIS

Abstract

Following an acute myocardial infarction (MI), ACE inhibitor therapy improves ventricular function, prolongs survival and decreases infarct size. Currently, ACE inhibitors are not indicated for use in the prevention of ischaemia in patients with coronary artery disease (CAD). However, evidence is mounting to suggest that quinapril may find a use in this indication. Results from a 1-year follow-up of the QUinapril On Vascular Ace and Determinants of ISchaemia (QUO VADIS) study suggest that long-term ACE inhibition with quinapril reduces ischaemic events in patients who have undergone coronary artery bypass graft (CABG) surgery. These beneficial effects may be unrelated to the BP-lowering effects of quinapril, delegates were told at the 71st Scientific Sessions of the American Heart Association [ Dallas, US; November 1998 ].